← SynDRA
ULIXERTINIB
SynDRA canonical compound SYN0038328 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Mechanism of action | MAP kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- MAPK3 INHIBITOR
- MAP kinase ERK1 inhibitor
- MAPK1 INHIBITOR
- MAP kinase ERK2 inhibitor
- MEK inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- PRKCD
- PFKP
- PDXK
- PDGFRB
- PASK
- PAK6
- PAK4
- PAK2
- PAICS
- OPA1
- NUAK2
- NTRK1
- NQO2
- NLK
- NEK9
- NEK7
- PGRMC1
- PHKG2
- PIM1
- PRKACA
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACG
- PRKACB
- PRKAA1
- PIP4K2A
- PLK4
- PLK1
- PKN2
- PKN1
- PKMYT1
- PIP4K2C
- NEK3
- NEK2
- NEK1
- MAPK10
- MAPK9
Cross-references
Synonyms
- BVD-523
- BVD-ERK
- ULIXERTINIB (BVD-523)
- VRT-752271
- VRT752271
- BVD 523
- ulixertinibum
- RefChem:192996
- Ulixertinib [INN]
- Ulixertinib (BVD-523)
- UNII-16ZDH50O1U
- Ulixertinib (BVD-523, VRT752271)
- Ulixertinib (INN)
- MFCD22543853
- MFCD22628898
- Ulixertinib (BVD-523,VRT752271)
- BVD523 HCl
- BVD-523 HCl
- ULIXERTINIB [WHO-DD]
- GTPL9210
- orb1300149
- SCHEMBL14211742
- SCHEMBL29456946
- SCHEMBL29712842
- GLXC-90461
- EX-A1332
- BDBM50094465
- NSC797771
- NSC800959
- s7854
- AKOS025396467
- CCG-269049
- EBC-218036
- NSC-797771
- NSC-800959
- NCGC00378692-02
- NCGC00378692-04
- NCGC00378692-05
- NCGC00378692-07
Look up ULIXERTINIB in the interactive SynDRA portal →